Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce its plans to conduct
TAKE NOTICE that the Annual General Meeting of Shareholders of the Company will be held at the time, date and place specified below: Time: 11.00 am
In May, Imagion signed a collaboration agreement with Siemens Healthineers to explore the utility of our MagSense nanoparticles as a contrast agent in MRI scanning.
Imagion Biosystems Limited is pleased to report that the first phase of manufacturing of the MagSense® HER2 nanoparticle formulation under Good Manufacturing Practice (GMP) conditions
Imagion Biosystems Limited announces it has entered into a collaboration agreement with Siemens Healthcare Pty Ltd of Australia (Siemens Healthineers) to further explore the utility
Imagion Biosystems Limited is pleased to share news of a recent publication, led by researchers at the Weill Cornell Medical College, which reports use of
Imagion Biosystems Limited is pleased to provide investors with its May 2020 Investor Newsletter. The newsletter details recent key company developments and activities including: Message
Imagion Biosystems Limited has announced “Appendix 3X: Initial Director’s Interest Notice.” Read Appendix 3X.
Imagion Biosystems Limited today announced the appointment of Ms Dianne Angus to the Board of Directors. Ms Angus joined the Board as a Non-Executive Director
Five Appendices 3Y, “Change of Director’s Interest Notice”, have been released to announce the entitlement right offers taken up by Imagion Directors. Read the Appendices